Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacture of generic drugs. It ranked 100th in the Fortune India 500 list in 2020. Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company offers products in the therapeutic areas of pain management, neurology, dermatology, rare diseases, specialty oncology, gastroenterology, and liver diseases. It also provides consumer wellness products, such as Sugar Free and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India. The ISIN of this stock is INE010B01027.